X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-09-20 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $250.05 | -127,308 | 6,721,590 | -2% | -$31,833,495 | |||||
| M | 2023-09-20 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $250.05 | -127,308 | 5,914,947 | -2% | -$31,833,495 | |||||
| D | 2023-09-19 | IQV | Iqvia Holdings Inc. | Panagos Constantinos | See Remarks | S - Sale+OE | $208.67 | -27,317 | 14,250 | -66% | -$5,700,340 | |||||
| M | 2023-09-18 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $263.89 | -190,764 | 6,042,255 | -3% | -$50,339,894 | |||||
| M | 2023-09-18 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $263.89 | -190,764 | 6,848,898 | -3% | -$50,339,894 | |||||
2023-09-14 | ISPC | Ispecimen Inc. | Bielak Benjamin | Chief Info Officer, Secretary | P - Purchase | $0.72 | +18,000 | 84,348 | +27% | +$12,960 | ||||||
2023-09-01 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale | $65.13 | -8,449 | 77,530 | -10% | -$550,283 | ||||||
| DM | 2023-08-28 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.70 | -5,000 | 120,583 | -4% | -$18,500 | |||||
2023-08-24 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | P - Purchase | $198.79 | +1,000 | 23,528 | +4% | +$198,786 | ||||||
2023-08-24 | MLCT | Malachite Innovations, Inc. | Indemnity National Insurance Co | 10% | P - Purchase | $0.15 | +6,666,667 | 33,333,333 | +25% | +$1,000,000 | ||||||
| D | 2023-08-14 | MEDP | Medpace Holdings, Inc. | Kraft Robert O. | Dir | S - Sale+OE | $265.67 | -13,782 | 188 | -99% | -$3,661,464 | |||||
| D | 2023-08-14 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | P - Purchase | $5.48 | +45,000 | 2,332,919 | +2% | +$246,600 | |||||
| D | 2023-08-10 | CRL | Charles River Laboratories International, Inc. | Barbo William D | Corporate EVP, CCO | S - Sale+OE | $217.24 | -5,763 | 28,737 | -17% | -$1,251,954 | |||||
| D | 2023-08-10 | CRL | Charles River Laboratories International, Inc. | Knell Michael Gunnar | CSVP, Chief Accounting Officer | S - Sale+OE | $216.54 | -1,471 | 9,940 | -13% | -$318,530 | |||||
2023-08-10 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $216.52 | -700 | 24,983 | -3% | -$151,564 | ||||||
2023-08-01 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale | $63.28 | -21,511 | 97,583 | -18% | -$1,361,216 | ||||||
| D | 2023-07-31 | MEDP | Medpace Holdings, Inc. | Brady Kevin M. | CFO, Treasurer | S - Sale+OE | $255.00 | -7,000 | 6,000 | -54% | -$1,785,000 | |||||
| D | 2023-07-27 | MEDP | Medpace Holdings, Inc. | Ewald Stephen P | GC, Corp. Secy. | S - Sale+OE | $254.39 | -21,850 | 14,854 | -60% | -$5,558,422 | |||||
| D | 2023-07-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.75 | -5,000 | 120,583 | -4% | -$23,750 | |||||
2023-07-14 | FOXO | Foxo Technologies Inc. | Dowling Vincent J. Jr | 10% | S - Sale | $0.16 | -3,000 | 4,647,405 | 0% | -$491 | ||||||
| DM | 2023-07-10 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.03 | -30,000 | 333,197 | -8% | -$150,852 | |||||
| DM | 2023-06-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.44 | -15,000 | 120,583 | -11% | -$66,603 | |||||
| M | 2023-06-23 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.05 | -2,091 | 5,170,075 | 0% | -$94,202 | |||||
| M | 2023-06-20 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.01 | -19,346 | 5,172,166 | 0% | -$870,678 | |||||
| M | 2023-06-14 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.04 | -33,027 | 5,191,512 | -1% | -$1,487,540 | |||||
| DM | 2023-06-13 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.04 | -43,851 | 333,197 | -12% | -$220,859 | |||||
| M | 2023-06-12 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.05 | -2,000 | 5,224,539 | 0% | -$90,101 | |||||
| M | 2023-06-08 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.34 | -12,626 | 5,226,539 | 0% | -$572,478 | |||||
2023-06-09 | OABI | Omniab, Inc. | Foehr Matthew W | CEO | P - Purchase | $4.52 | +115,000 | 2,574,009 | +5% | +$519,800 | ||||||
2023-06-08 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $220.85 | -49,347 | 7,039,662 | -1% | -$10,898,285 | ||||||
2023-06-08 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $220.85 | -49,347 | 6,233,019 | -1% | -$10,898,285 | ||||||
| M | 2023-06-06 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $222.15 | -169,005 | 7,089,009 | -2% | -$37,544,581 | |||||
| M | 2023-06-06 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $222.15 | -169,005 | 6,282,366 | -3% | -$37,544,581 | |||||
| M | 2023-06-05 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.86 | -38,629 | 5,239,165 | -1% | -$1,771,404 | |||||
2023-06-05 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale | $201.89 | -5,820 | 1,973 | -75% | -$1,175,000 | ||||||
| M | 2023-05-31 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.25 | -21,095 | 5,277,794 | 0% | -$954,495 | |||||
2023-05-31 | ISPC | Ispecimen Inc. | Curley Tracy | CEO, CFO, Treasurer | P - Purchase | $1.25 | +4,400 | 49,541 | +10% | +$5,500 | ||||||
2023-05-26 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale | $198.66 | -1 | 7,793 | 0% | -$199 | ||||||
2023-05-23 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.00 | -29,000 | 5,298,889 | -1% | -$1,305,000 | ||||||
| D | 2023-05-23 | OABI | Omniab, Inc. | Higgins John L | Dir | S - Sale+OE | $4.05 | -9,000 | 2,462,686 | 0% | -$36,450 | |||||
| D | 2023-05-19 | OABI | Omniab, Inc. | Higgins John L | Dir | S - Sale+OE | $4.05 | -1,000 | 2,462,686 | 0% | -$4,050 | |||||
| D | 2023-05-18 | OABI | Omniab, Inc. | Higgins John L | Dir | S - Sale+OE | $3.89 | -50,000 | 2,462,686 | -2% | -$194,500 | |||||
2023-05-15 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $190.39 | -345 | 24,026 | -1% | -$65,685 | ||||||
2023-05-12 | OABI | Omniab, Inc. | Foehr Matthew W | CEO | P - Purchase | $3.40 | +440,000 | 2,438,414 | +22% | +$1,496,000 | ||||||
2023-05-12 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $193.03 | -959 | 24,371 | -4% | -$185,116 | ||||||
2023-05-11 | CRL | Charles River Laboratories International, Inc. | Massaro George | Dir | S - Sale | $193.43 | -288 | 4,964 | -5% | -$55,708 | ||||||
| D | 2023-05-03 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.02 | -16,149 | 333,197 | -5% | -$81,068 | |||||
| M | 2023-04-19 | MLCT | Malachite Innovations, Inc. | Feighan Edward F | Dir | P - Purchase | $0.20 | +50,000 | 3,074,250 | +2% | +$9,956 | |||||
2023-04-25 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $221.83 | -31,648 | 7,258,014 | 0% | -$7,020,476 | ||||||
2023-04-25 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $221.83 | -31,648 | 6,451,371 | 0% | -$7,020,476 | ||||||
| M | 2023-04-21 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $45.03 | -1,300 | 5,327,889 | 0% | -$58,537 | |||||
| D | 2023-04-11 | MLCT | Malachite Innovations, Inc. | Feighan Edward F | Dir | P - Purchase | $0.15 | +333,333 | 3,024,250 | +12% | +$50,000 | |||||
| DM | 2023-04-10 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.00 | -14,134 | 0 | -100% | -$70,670 | |||||
| DM | 2023-04-10 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.00 | -15,000 | 333,197 | -4% | -$75,000 | |||||
| DM | 2023-04-05 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.02 | -34,160 | 0 | -100% | -$171,616 | |||||
| DM | 2023-04-05 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.02 | -34,823 | 333,197 | -9% | -$174,951 | |||||
| DM | 2023-03-31 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.02 | -9,973 | 0 | -100% | -$50,084 | |||||
| DM | 2023-03-31 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.02 | -10,177 | 333,197 | -3% | -$51,110 | |||||
| M | 2023-03-31 | NRC | National Research Corp | Raasch Jona S | COO, NRC Health | S - Sale | $43.61 | -23,931 | 12,951 | -65% | -$1,043,512 | |||||
| M | 2023-03-29 | NRC | National Research Corp | Raasch Jona S | COO, NRC Health | S - Sale | $43.49 | -25,000 | 36,882 | -40% | -$1,087,262 | |||||
2023-03-14 | NOTV | Inotiv, Inc. | Sagartz John E | Chief Strategy Officer | P - Purchase | $4.91 | +5,100 | 692,047 | +1% | +$25,041 | ||||||
| M | 2023-02-24 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale | $45.68 | -11,912 | 5,384 | -69% | -$544,096 | |||||
2023-02-23 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | P - Purchase | $220.73 | +1,750 | 21,864 | +9% | +$386,278 | ||||||
2023-02-22 | NOTV | Inotiv, Inc. | Beattie John Gregory | COO | P - Purchase | $6.99 | +5,000 | 63,795 | +9% | +$34,950 | ||||||
| D | 2023-02-16 | CRL | Charles River Laboratories International, Inc. | Parisotto Shannon M | CEVP, Disc, Safety Assessment | S - Sale+OE | $254.41 | -4,558 | 35,046 | -12% | -$1,159,619 | |||||
| M | 2023-02-16 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $47.03 | -6,205 | 5,329,189 | 0% | -$291,838 | |||||
| D | 2023-02-16 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP, COO | S - Sale+OE | $254.39 | -3,205 | 41,038 | -7% | -$815,310 | |||||
2023-02-16 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale | $225.61 | -4,446 | 7,794 | -36% | -$1,003,068 | ||||||
2023-02-15 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | S - Sale | $250.00 | -20,000 | 258,902 | -7% | -$5,000,017 | ||||||
| D | 2023-02-14 | IQV | Iqvia Holdings Inc. | Sherbet Eric | See Remarks | S - Sale+OE | $230.00 | -1,000 | 17,053 | -6% | -$230,000 | |||||
2023-02-07 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $47.03 | -100 | 5,335,394 | 0% | -$4,703 | ||||||
2023-02-02 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $47.34 | -100 | 5,335,494 | 0% | -$4,734 | ||||||
| DM | 2023-02-01 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.72 | -29,133 | 0 | -100% | -$166,517 | |||||
| DM | 2023-02-01 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.72 | -30,000 | 333,197 | -8% | -$171,553 | |||||
| D | 2023-01-31 | INCY | Incyte Corp | Pasquale Maria E | EVP, GC | S - Sale+OE | $84.06 | -802 | 68,524 | -1% | -$67,416 | |||||
| D | 2023-01-30 | INCY | Incyte Corp | Pasquale Maria E | EVP, GC | S - Sale+OE | $84.74 | -60,024 | 68,524 | -47% | -$5,086,569 | |||||
| D | 2023-01-26 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale+OE | $85.00 | -7,000 | 42,835 | -14% | -$595,000 | |||||
2023-01-26 | INCY | Incyte Corp | Dhanak Dashyant | EVP, Chief Scientific Officer | S - Sale | $85.00 | -2,419 | 53,263 | -4% | -$205,615 | ||||||
2023-01-12 | DKDCA | Data Knights Acquisition Corp. | Shaolin Capital Management LLC | 10% | S - Sale | $10.48 | -100,000 | 400,000 | -20% | -$1,048,000 | ||||||
2023-01-09 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.72 | -6,370 | 5,335,594 | 0% | -$259,387 | ||||||
2023-01-04 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale | $79.78 | -28,399 | 109,021 | -21% | -$2,265,672 | ||||||
| DM | 2023-01-03 | MXCT | Maxcyte, Inc. | Doerfler Douglas | Pres, CEO | S - Sale+OE | $5.08 | -30,000 | 333,197 | -8% | -$152,430 | |||||
| DM | 2023-01-03 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.08 | -29,133 | 0 | -100% | -$148,051 | |||||
2022-12-09 | NOTV | Inotiv, Inc. | Pitchford William D | CHRO | S - Sale | $5.82 | -2,123 | 74,051 | -3% | -$12,366 | ||||||
| D | 2022-12-23 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale+OE | $80.80 | -17,324 | 37,855 | -31% | -$1,399,739 | |||||
2022-12-19 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $82.16 | -1,223 | 16,606 | -7% | -$100,482 | ||||||
2022-12-12 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | P - Purchase | $3.77 | +150,000 | 1,838,084 | +9% | +$564,765 | ||||||
2022-12-06 | OABI | Omniab, Inc. | Cochran Jennifer R. | Dir | P - Purchase | $3.75 | +22,250 | 77,476 | +40% | +$83,527 | ||||||
| DM | 2022-12-02 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, Global Sales, Marketing | S - Sale+OE | $5.81 | -29,133 | 0 | -100% | -$169,303 | |||||
| D | 2022-12-02 | CRL | Charles River Laboratories International, Inc. | Barbo William D | Corporate EVP, CCO | S - Sale+OE | $219.91 | -3,205 | 22,838 | -12% | -$704,814 | |||||
2022-12-02 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | P - Purchase | $218.90 | +1,500 | 20,114 | +8% | +$328,350 | ||||||
| D | 2022-12-01 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale+OE | $224.25 | -6,409 | 20,232 | -24% | -$1,437,205 | |||||
| D | 2022-08-31 | BIAF | Bioaffinity Technologies, Inc. | Knight Peter S | Dir | P - Purchase | $0.00 | +8,163 | 22,448 | +57% | +$0 | |||||
| D | 2022-08-31 | BIAF | Bioaffinity Technologies, Inc. | Anderson Robert A. | Dir | P - Purchase | $0.00 | +4,081 | 4,081 | New | +$0 | |||||
2022-12-01 | NOTV | Inotiv, Inc. | Neff R Matthew | Dir | S - Sale | $6.12 | -1,000 | 62,388 | -2% | -$6,120 | ||||||
| D | 2022-08-31 | BIAF | Bioaffinity Technologies, Inc. | Diamond Stuart | Dir | P - Purchase | $0.00 | +4,081 | 4,081 | New | +$0 | |||||
2022-11-30 | SBFM | Sunshine Biopharma, Inc | Sebaaly Camille | CFO, Secretary | P - Purchase | $0.76 | +30,000 | 174,465 | +21% | +$22,905 | ||||||
2022-11-30 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | P - Purchase | $3.39 | +300,000 | 1,705,350 | +21% | +$1,016,340 | ||||||
2022-11-28 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | P - Purchase | $2.81 | +10,000 | 170,062 | +6% | +$28,100 | ||||||
| D | 2022-09-01 | BIAF | Bioaffinity Technologies, Inc. | Edwards James Michael | CFO | P - Purchase | $0.00 | +2,448 | 36,815 | +7% | +$0 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |